Objective: Taking Company A's third-generation targeted drugs for lung cancer as an example, the paper analyzed the strategies of drug companies to deal with the dynamic adjustment of the medical insurance drug catalogue. Methods: Semi-structured interview was used to understand the views of relevant personnel on the adjustment of medical insurance policy, the questionnaire survey was used to understand the changes in patients' satisfaction with medication, and typical cases were used to analyze the changes in the sales of targeted drugs before and after they were included in the medical insurance catalogue. Results: After drugs were included in the list of medical insurance, drug prices decreased significantly, drug sales increased significantly, and patients’ satisfaction with drug increased significantly. Conclusions: Pharmaceutical enterprises should continue to improve corporate strategy, enhance innovation and research, stabilize drug quality and efficacy, and actively cope with a new round of adjustment of national medical insurance catalogue.